Personalized Medication Solutions
RxMapper uses DNA to match patients with the right medications at the right doses — eliminating trial-and-error prescribing and reducing medication-related costs.
Our Mission
Solve the Lack of Precision in Prescribing MedicationsStarting with your DNA
The current trial-and-error approach to the prescribing of medications results in poor health outcomes and is driving runaway costs in drug spend.
of Drugs Prescribed are the Wrong Drug or Dose1
of Cancer Drugs are the Wrong Drug or Dose2
in Estimated Annual Cost of Harm caused by Wrong Drug Prescriptions3
of Patients Do Not Take their Medications as Prescribed4
1Spear, B.B., M. Heath-Chiozzi, and J. Huff, Clinical application of pharmacogenetics. Trends Mol Med, 2001. 7(5): p. 201-4.
2Spear, B.B., M. Heath-Chiozzi, and J. Huff, Clinical application of pharmacogenetics. Trends Mol Med, 2001. 7(5): p. 201-4.
3Watanabe, J.H., T. McInnis, and J.D. Hirsch, Cost of Prescription Drug-Related Morbidity and Mortality. Ann Pharmacother, 2018. 52(9): p. 829-837.
4Ellwood, M., et al., Enhancing Prescription Medication Adherence: A National Plan, N.C.o.P.I.a. Education, Editor. 2007, Patient Safety Network: PSNet.
Drugs don't work in patients who don't take them.
— C. Everett Koop, U.S. Surgeon General
The RxMapper Advantage
The Impact
of patients sequenced by RxMapper receive personalized medication recommendations — giving them the chance to live healthier, happier lives.
Unmatched Scope
Covers 6,500+ medications across all major therapeutic categories — the most comprehensive PGx database available.
On-Call Support
Dedicated clinical pharmacists available to members and prescribers for real-time medication consultation.
High-Cost Risk Containment
Proactively identifies members at risk for expensive specialty medications before the claim occurs.
Proven Financial Impact
Average employer savings of $20,697 per member, with 8.5x–13x ROI demonstrated in real-world deployments.
Clinical Examples
Real Patients. Real Results.
Matthew
Rheumatoid Arthritis
CYP1A2 variant identified — poor responder to Methotrexate, experiencing significant side effects with no relief.
Switched to Biologic therapy per MapperHealth guidance — 90% symptom reduction within 3 months.
Katie
Breast Cancer
CYP2D6 poor metabolizer — Tamoxifen was being prescribed at standard dose, providing minimal therapeutic effect.
Switched to Letrozole — optimal treatment response and improved quality of life.
Tommy
OCD / Generalized Anxiety
Three years of failed SSRI trials — genomic markers showing poor metabolism were never considered.
RxMapper matched SNRI therapy — 80% symptom relief on first genomically-guided prescription.
Stop Paying for Medications That Don't Work
Join thousands of employers and health plans transforming member outcomes with precision genomics.
Request a Demo